• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

    6/30/21 8:30:00 AM ET
    $BGNE
    $LEGN
    $MTEM
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email

    NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director.

    "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeutics for patients who have no other treatment options," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

    Dr. Sanders most recently served as strategic advisor to the Chief Medical Officer (CMO) of Celgene, following Celgene's acquisition of Juno where she was an Executive Vice President of Development Operations. She also served as Transition Advisor to Bristol Myers Squibb (BMS), which acquired Celgene. In those roles, she ensured the effective integration of Juno's Chimeric Antigen Receptor T (CAR-T) Cell Development Organization into the Celgene and BMS organizations. Prior to that, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as Senior Vice President, Global Head of Clinical Operations and Industry Collaboration, for six years.

    "The ability to quickly develop effective medicines is critically important in rare diseases, where patients have few or no treatment options," said Dr. Sanders. "I am thrilled to join the Ultragenyx Board and support the executive team as it works diligently to make a significant impact on these patient populations."

    Currently, Dr. Sanders serves as a member of the Board of Directors of several biotechnology companies including Beigene Ltd. (NASDAQ:BGNE), Molecular Templates Inc. (NASDAQ:MTEM), Legend Biotech Corporation (NASDAQ:LEGN), and AltruBio (formerly AbGenomics) Inc. She is a member of the Board of Trustees and Chair of the Research Ethics Committee for the Fred Hutchinson Cancer Research Center, a non-profit cancer research organization in Seattle. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.

    About Ultragenyx Pharmaceutical Inc.

    Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

    The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

    For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

    Contact Ultragenyx Pharmaceutical Inc.

    Investors & Media

    Joshua Higa

    415-475-6370



    Primary Logo

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE
    $LEGN
    $MTEM
    $RARE

    CompanyDatePrice TargetRatingAnalyst
    Ultragenyx Pharmaceutical Inc.
    $RARE
    5/28/2025Outperform
    William Blair
    BeiGene Ltd.
    $BGNE
    12/3/2024$300.00Overweight
    Morgan Stanley
    Legend Biotech Corporation
    $LEGN
    10/8/2024$86.00Buy
    Redburn Atlantic
    BeiGene Ltd.
    $BGNE
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    Legend Biotech Corporation
    $LEGN
    6/17/2024$88.00Buy
    Truist
    Ultragenyx Pharmaceutical Inc.
    $RARE
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    Legend Biotech Corporation
    $LEGN
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    Legend Biotech Corporation
    $LEGN
    5/23/2024$60.00Buy
    Deutsche Bank
    More analyst ratings

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ultragenyx Pharma

      William Blair initiated coverage of Ultragenyx Pharma with a rating of Outperform

      5/28/25 9:09:46 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on BeiGene with a new price target

      Morgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00

      12/3/24 8:35:59 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Legend Biotech with a new price target

      Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00

      10/8/24 7:29:11 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      4/4/24 8:13:35 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the company's common stock to 20 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). T

      5/20/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program. Investors and other interested parties may join the live webcast through this weblink or visit Legend Biotech's website under Events and Pre

      5/19/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BGNE
    $LEGN
    $MTEM
    $RARE
    SEC Filings

    See more
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      5/22/25 8:38:48 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      5/19/25 5:03:38 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      5/14/25 9:00:18 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Financials

    Live finance-specific insights

    See more
    • Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

      CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia's TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biotech believes will provide financial runway into the second quarter of 2026 SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend

      5/13/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/10/24 9:30:34 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/4/24 4:05:33 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/18/24 9:49:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suliman Shehnaaz was granted 5,740 shares, increasing direct ownership by 28% to 25,940 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/19/25 6:34:32 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Welch Daniel G was granted 5,740 shares, increasing direct ownership by 21% to 32,690 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/19/25 6:33:56 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sanders Corazon (Corsee) D. was granted 5,740 shares, increasing direct ownership by 48% to 17,749 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/19/25 6:33:25 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    $LEGN
    $MTEM
    $RARE
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities